» Articles » PMID: 35666090

Self-emulsifying Drug Delivery Systems: a Novel Approach to Deliver Drugs

Overview
Journal Drug Deliv
Specialty Pharmacology
Date 2022 Jun 6
PMID 35666090
Authors
Affiliations
Soon will be listed here.
Abstract

Self-emulsifying drug delivery systems (SEDDS) are a proven method for poorly soluble substances works by increasing the solubility and bioavailability. SEDDS and isotropic mixtures, are composed of oils, surfactants, and occasionally cosolvents. The ability of these formulations and methods to produce microemulsions or fine oil-in-water (o/w) emulsions after moderate stirring and dilution by water phase along the GI tract might be a promising technique for lipophilic agents with dissolution rate-limited absorption. This review provides an outline of SEDDS's numerous advances and biopharmaceutical elements, types, manufacturing, characterization, limitations, and future prospects. The evaluation of SEDDS and its applications are also discussed, focusing on the advances of SEDDS's solid self-emulsifying delivery mechanism and dosage form. By integrating suitable polymer into the formulation, SEDDS may be studied for the creation of a formulation with sustained drug release. This technology's improvement might lead to a new application in the field of medicine delivery. SEDDS has been demonstrated to be quite efficient in increasing oral bioavailability of lipophilic products. SEDDS is one of the promising methods for controlling the characteristics of medications that are not great choices for oral delivery. It is also worth mentioning that SEDDS may be made in variety of solid dosage forms that are acceptable for both oral and parenteral administration.

Citing Articles

Oral pH-Sensitive Solid Self-Microemulsion of Norcantharidin Wrapped in Colon-Coated Capsule for Selective Therapy of Colorectal Carcinoma.

Liu X, Fang W, Lu W, Xu M, Wu Z, Su D AAPS PharmSciTech. 2025; 26(3):67.

PMID: 39979516 DOI: 10.1208/s12249-025-03056-0.


Self-Emulsifying Drug Delivery Systems (SEDDS): Transition from Liquid to Solid-A Comprehensive Review of Formulation, Characterization, Applications, and Future Trends.

Uttreja P, Karnik I, Youssef A, Narala N, Elkanayati R, Baisa S Pharmaceutics. 2025; 17(1).

PMID: 39861711 PMC: 11768142. DOI: 10.3390/pharmaceutics17010063.


Solubilization techniques used for poorly water-soluble drugs.

Xie B, Liu Y, Li X, Yang P, He W Acta Pharm Sin B. 2024; 14(11):4683-4716.

PMID: 39664427 PMC: 11628819. DOI: 10.1016/j.apsb.2024.08.027.


Lipid-Based Nanoformulations for Drug Delivery: An Ongoing Perspective.

Rehman M, Tahir N, Sohail M, Qadri M, Duarte S, Brandao P Pharmaceutics. 2024; 16(11).

PMID: 39598500 PMC: 11597327. DOI: 10.3390/pharmaceutics16111376.


A Systematic Review: Quercetin-Secondary Metabolite of the Flavonol Class, with Multiple Health Benefits and Low Bioavailability.

Frent O, Stefan L, Morgovan C, Duteanu N, Dejeu I, Marian E Int J Mol Sci. 2024; 25(22).

PMID: 39596162 PMC: 11594109. DOI: 10.3390/ijms252212091.


References
1.
Singh B, Beg S, Khurana R, Sandhu P, Kaur R, Katare O . Recent advances in self-emulsifying drug delivery systems (SEDDS). Crit Rev Ther Drug Carrier Syst. 2014; 31(2):121-85. DOI: 10.1615/critrevtherdrugcarriersyst.2014008502. View

2.
Setthacheewakul S, Kedjinda W, Maneenuan D, Wiwattanapatapee R . Controlled release of oral tetrahydrocurcumin from a novel self-emulsifying floating drug delivery system (SEFDDS). AAPS PharmSciTech. 2010; 12(1):152-64. PMC: 3066365. DOI: 10.1208/s12249-010-9568-8. View

3.
Feeney O, Crum M, McEvoy C, Trevaskis N, Williams H, Pouton C . 50years of oral lipid-based formulations: Provenance, progress and future perspectives. Adv Drug Deliv Rev. 2016; 101:167-194. DOI: 10.1016/j.addr.2016.04.007. View

4.
Cherniakov I, Domb A, Hoffman A . Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects. Expert Opin Drug Deliv. 2015; 12(7):1121-33. DOI: 10.1517/17425247.2015.999038. View

5.
Akula S, Gurram A, Devireddy S . Self-Microemulsifying Drug Delivery Systems: An Attractive Strategy for Enhanced Therapeutic Profile. Int Sch Res Notices. 2016; 2014:964051. PMC: 4897095. DOI: 10.1155/2014/964051. View